(Press-News.org) Apixaban (trade name Eliquis) has been approved since July 2014 for acute treatment of adults with deep vein thrombosis or pulmonary embolism. In addition, the drug can be used for low-dose long-term treatment to prevent recurrent thrombosis or pulmonary embolism. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether in these cases the drug offers patients an added benefit over the appropriate comparator therapies.
According to the findings, considerable added benefit of apixaban is proven for the initial treatment of patients with a body mass index (BMI) of over 28 kg/m². In contrast, an added benefit versus the appropriate comparator therapy is neither proven for initial treatment of patients with lower BMI, nor for long-term prevention - irrespective of the BMI.
Third dossier assessment because of new therapeutic indication
Apixaban is an anticoagulant, a type of drug that prevents blood-clotting. After the dossier assessments on apixaban in hip replacement (2012) and atrial fibrillation (2013), and following another expansion of approval, the Institute now investigated which advantages and disadvantages the drug has in comparison with the appropriate comparator therapy in the therapeutic indications "deep vein thrombosis" and "pulmonary embolism". In vein thrombosis, a blood clot blocks a vein, usually in the lower leg or thigh. A blood clot that travels to the lungs, however, can cause life-threatening pulmonary embolism.
The Federal Joint Committee (G-BA) posed two research questions and accordingly specified two appropriate comparator therapies: As initial treatment, apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) was to be compared with a vitamin K antagonist, which, until it unfolds its full effect, was to be supplemented with a heparin in the beginning of the treatment. As long-term prevention, i.e. to prevent recurrent deep vein thrombosis or pulmonary embolism, low-dose apixaban (2.5 mg twice daily) was to be compared with a vitamin K Antagonist.
Only one study on one research question
The dossier submitted by the drug manufacturer contained no data on the second research question, however. Hence the added benefit of apixaban in long-term prevention is not proven. For the first research question, initial treatment after occurrence of pulmonary embolism or deep vein thrombosis, the manufacturer presented data from a single randomized controlled trial: In the AMPLIFY study, apixaban was administered for six months. In the comparator arm, enoxaparin was used as low molecular weight heparin, and warfarin as vitamin K antagonist.
Effect modifier BMI
For some patient-relevant outcomes, there was no proof of an advantage or disadvantage of apixaban versus the comparator therapy: In mortality and treatment discontinuations due to adverse events, there were no statistically significant differences between the study arms. Health-related quality of life was not investigated in the study.
For the outcome "symptomatic non-fatal deep vein thrombosis", the data suggested effect modification by the characteristic "BMI": Whereas there is a hint of an added benefit of apixaban in patients with a BMI of over 28 kg/m², an added benefit of the drug is not proven in patients with lower BMI. The BMI also modified the effect in the outcome "symptomatic non-fatal pulmonary embolism": In patients with a BMI of up to 28 kg/m², there is an indication of lesser benefit of apixaban in comparison with enoxaparin and warfarin; in a BMI of 28 kg/m² or higher, there is no difference.
Fewer bleeding events
Irrespective of the BMI, treatment with apixaban had advantages with respect to two side effect outcomes: In major bleeding, there was an indication of lesser harm. In the clinically relevant non-major bleeding events, the results were considered to be so robust that even proof of lesser harm from apixaban than from enoxaparin and warfarin could be derived although there was only one study.
Overall, in the initial treatment of deep vein thrombosis and pulmonary embolism, considerable added benefit of apixaban versus the appropriate comparator therapy is therefore proven for patients with a BMI of over 28 kg/m². For the initial treatment of patients with a BMI of up to 28 kg/m², in contrast, an added benefit is not proven. For long-term prevention, an added benefit of apixaban is also not proven.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessments according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on apixaban.
The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book V and specific German-language information on the assessment of apixaban. More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org).
If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
Wencui Han of the Department of ...
The El Niño Southern Oscillation is Earth's main source of year-to-year climate variability, but its response to global warming remains highly uncertain.
Scientists see a large amount of variability in the El Niño-Southern Oscillation (ENSO) when looking back at climate records from thousands of years ago. Without a clear understanding of what caused past changes in ENSO variability, predicting the climate phenomenon's future is a difficult task. A new study shows how this climate system responds to various pressures, such as changes in carbon dioxide and ice ...
Athens, Ga. - A new article detailing the relationship of two U.S. Supreme Court cases and how they work together to uphold freedom of expression has been published in the Georgia Law Review by William E. Lee, professor of journalism in the University of Georgia Grady College of Journalism and Mass Communication.
Lee's article focuses on New York Times v. Sullivan and its companion case, Abernathy v. Sullivan, in which the court upheld the First Amendment rights of both the press and ministers active in the civil rights movement. These rulings affect today's citizen ...
Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so. In a mouse model they developed, the ...
This news release is available in German.
How can light which has been captured in a solar cell be examined in experiments? Jülich scientists have succeeded in looking directly at light propagation within a solar cell by using a trick. The photovoltaics researchers are working on periodic nanostructures that efficiently capture a portion of sunlight which is normally only poorly absorbed.
Until recently, light trapping within periodically nanostructured solar cells could only be analysed using indirect methods, as captured light is not visible from outside ...
Radio frequency identification (RFID) tags--devices that can transmit data over short distances to identify objects, animals or people--have become increasingly popular for tracking everything from automobiles being manufactured on an assembly line to zoo animals in transit to their new homes. Now, thanks to a new NIST report, the next beneficiaries of RFID technology may soon be law enforcement agencies responsible for the management of forensic evidence.
A typical RFID system consists of a microchip programmed with identifying data--the "tag"--and a two-way radio transmitter-receiver, ...
A study of more than 9,000 men with fertility problems has revealed a correlation between the number of different defects in a man's semen and the likelihood that the man has other health problems.
The study, conducted by investigators at the Stanford University School of Medicine, also links poor semen quality to a higher chance of having various specific health conditions, such as hypertension, and more generally to skin and endocrine disorders.
The findings, to be published online Dec. 10 in Fertility and Sterility, may spur more-comprehensive approaches to treating ...
Nagoya, Japan - Professor Stephan Irle and Yoshio Nishimoto at the Institute of Transformative Bio-Molecules (ITbM) of Nagoya University and Dr. Dmitri Fedorov of the National Institute of Advanced Industrial Science and Technology (AIST, Tsukuba) have developed a novel ultrafast quantum chemical method enabling rapid simulations of molecules containing more than a million atoms without detrimental loss in accuracy. This method consists of a combination of the Fragment Molecular Orbital (FMO) approach and the Density-Functional Tight-Binding (DFTB) method, called FMO-DFTB ...
PROVIDENCE, R.I. [Brown University] -- A "Viewpoint" published in JAMA urges readers to be patient with the new federal Open Payments Program database. The site, designed to report drug and device industry payments to physicians, debuted substantially incomplete, the authors wrote, but it is too important to dismiss before its shortcomings are addressed.
"Viewed in the abstract, the value inherent in the transparency offered by the OPP database is beyond dispute," wrote Dr. Eli Y. Adashi, former dean of medicine and biological sciences at Brown University, and Sachin ...
A research team led by physicists at the University of Wisconsin-Milwaukee (UWM) has proven a method that makes it possible to find the atomic structure of proteins in action by producing "snapshots" of them with unprecedented spatial and temporal resolution.
What made it possible were the ultra-short X-ray pulses of a Free Electron Laser (XFEL).
Physics professor Marius Schmidt and doctoral student Jason Tenboer recently completed the experiment with the XFEL at the Stanford Linear Accelerator Center (SLAC) in California.
It confirms that the XFEL imaging method, ...
